| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Ticho Barry, CHIEF MEDICAL OFFICER
Sold 7,195 shares ($190K) |
| 03 Nov 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
–Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open-label treatment period; data readout antic... |
| 21 Oct 2026 | 144 |
| 02 Oct 2026 |
Form 4: Allan Jonathan, GENERAL COUNSEL & CORP SEC
Sold 627 shares ($16.5K) |
| 02 Oct 2026 |
Form 4: Ticho Barry, CHIEF MEDICAL OFFICER
Sold 1,051 shares ($27.5K) |
| 02 Oct 2026 | 144 |
| 30 Sep 2026 | SCHEDULE 13G |
| 25 Sep 2026 |
Form 4: Cumbo Alexander, Director
Granted 39,674 Director Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 3: Cumbo Alexander, Director
No securities owned |
| 25 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 03 Sep 2026 |
Form 4: Ticho Barry, CHIEF MEDICAL OFFICER
Sold 5,545 shares ($170K) |
| 18 Aug 2026 |
Form 4: Ticho Barry, CHIEF MEDICAL OFFICER
Received 10,000 shares by exercise or conversion · Sold 4,767 shares ($153K) |
| 18 Aug 2026 |
Form 4: Kaye Edward M. Md, Director
Received 26,250 shares by exercise or conversion · Sold 12,567 shares ($403K) |
| 18 Aug 2026 |
Form 4: Allan Jonathan, GENERAL COUNSEL & CORP SEC
Received 6,000 shares by exercise or conversion · Sold 2,861 shares ($91.6K) |
Loading...